Figure 4: C21 does not affect bone formation. | Nature Communications

Figure 4: C21 does not affect bone formation.

From: Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation

Figure 4

Bone formation and histomorphometry analyses of C57Bl/6J mice (a–d) treated with either vehicle or C21, between weeks 2 and 6 after ovariectomy (n=10–11 mice per group), according to Fig. 2e, and (e–p) treated with vehicle, C21 or alendronate for 4 weeks (n=5–8 mice per group). In distal femur, (a,e) osteoblast number over bone surface (N.Ob/BS). (b,f) mineral apposition rate (MAR) and (c,g) bone formation rate over bone surface (BFR/BS) determined by quantification of (h) the region of interest (dashed white lines) of calcein (green) and alizarin complexone (red)-labelled sections. Scale bar, 250 μm (top) or 20 μm (bottom). (d,i) P1NP serum concentration. (j) N.Oc/BS, osteoclast number over bone surface from the analysis of (k) the region of interest (white dashed lines) of Von Kossa-, alcian blue- and TRAP-stained femur sections. Scale bar, 300 μm (left panels) and 100 μm (right panels). Microcomputed tomography assessment of (l) BV/TV (m) bone mineral density (BMD), (n) trabecular number (Tb.N), (o) trabecular thickness (Tb.Th) and (p) trabecular spacing (Tb.Sp). All data in a–g,i–j and l–p are shown as the mean±s.e.m. NS, not significant; *P<0.05; **P<0.01; ***P<0.001; determined by Kruskal–Wallis test followed by Dunn’s multiple comparison test.

Back to article page